Akebia Therapeutics, Inc. (AKBA) Form 8-K — Oct 23, 2026
Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026 because its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 19, 2027 to regain compliance by closing at or above $1.00 for 10 consecutive business days, and may qualify for a second 180-day period.
Key figures
- Compliance period days
- 180
- Minimum bid price required
- $1.00
- Initial compliance deadline
- April 19, 2027
- Deficiency duration business days
- 30
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.